Change in number of shares and votes in Aerocrine etc.

With reference to Chapter 4 Section 9 in the Swedish Financial Instruments
Trading Act, it is hereby announced that as a result of the recent rights issue
in Aerocrine AB (Nasdaq Stockholm: AERO), the number of shares and votes in
Aerocrine has increased during February 2015 as specified in the table below.

                   Number of shares and votes
February 1, 2015                  155,416,387
Increase                          542,721,067
February 27, 2015                 698,137,454

It is further announced that Rolf Classon now has resumed his position as
chairman of the Board of Directors, after being on sick leave since December
2014.

Solna February 27, 2015

Aerocrine AB (publ.)

For further information, please contact:

Marshall Woodworth, CFO, +1 919 749 8748 or +46 709 695 219

About Aerocrine

Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as Asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® and NIOX
VERO®, which enables fast and reliable point-of-care measurement of airway
inflammation. These products plays a critical role in more effective diagnosis,
treatment and follow-up of patients affected with inflammatory airway diseases.
Aerocrine is based in Sweden with subsidiaries in the US, Germany, Switzerland
and the UK. Aerocrine shares have been listed on the Stockholm Stock Exchange
since 2007 (AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

+-----------------------------------------------------------------------------+
|Aerocrine is required to disclose the information provided herein pursuant to|
|the Securities Markets Act and/or the Financial Instruments Trading Act. The |
|information was submitted for publication at 08:00 am on February 27, 2015.  |
+-----------------------------------------------------------------------------+